Trey Mullinax has been suspended for six months after testing positive for a substance prohibited under the PGA Tour’s anti-doping policy.
The PGA Tour announced the disciplinary action Wednesday, saying the substance detected in Trey Mullinax’s test is included on the World Anti-Doping Agency’s banned list. The tour did not identify the substance or disclose further details about the circumstances surrounding the positive result.
In a statement provided by the tour, Trey Mullinax said the violation stemmed from medication he took to treat a medical condition first diagnosed during his college years. He acknowledged that he did not seek approval before using the medication, as required under the tour’s policy.
“My lack of knowledge is not an excuse,” Trey Mullinax said. “It was my responsibility to know the rules before taking any medication and I failed to do so. I want to be absolutely clear: I have never taken any substance with the intention of gaining a competitive advantage. Anyone who knows me knows how much I respect this game and the values it represents.”
Trey Mullinax is believed to be the ninth player suspended since the PGA Tour introduced drug testing in 2008. He is also the first player known to have been suspended under the policy since Byeong Hun An in October 2023.
An’s suspension followed his use of an over-the-counter cough medicine purchased in South Korea. The medication contained a substance banned under the tour’s anti-doping rules.
The suspension comes during a period of limited competitive activity for Trey Mullinax. He finished 150th in last year’s FedEx Cup standings, leaving him with conditional status for the 2026 season.
Trey Mullinax made only three starts during the spring, including one appearance on the Korn Ferry Tour. His most recent tournament was the Zurich Classic of New Orleans, where he last competed on April 27.
Under the terms of the suspension, Trey Mullinax will be eligible to return to competition on Jan. 16. That date falls one week before the start of the 2027 PGA Tour season, giving him an opportunity to resume his career as the new campaign begins.
The PGA Tour has historically released limited information about anti-doping cases, generally announcing the player’s name, the length of the suspension and the policy violation without publishing full testing details.
READ NEXT
